AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Purple Biotech Ltd.

Major Shareholding Notification Jun 12, 2018

7004_rns_2018-06-12_051bc453-e458-4ff6-bb9d-a31beaa684eb.pdf

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

SC 13G 1 d7910458_13-g.htm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

Kitov Pharma Ltd. (Name of Issuer)

Ordinary Shares, no par value (Title of Class of Securities)

49803V107 [1]

(CUSIP Number)

May 31, 2018

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[_] Rule 13d-1(b)

[X] Rule 13d-1(c)

[_] Rule 13d-1(d)

__________

__________________________

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

[1] Represents the CUSIP number for the American Depositary Shares, each representing 20 Ordinary Shares, no par value.

CUSIP No 49803V107

  1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Armistice Capital, LLC

    1. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  • (a) [_] (b) [_]

    1. SEC USE ONLY
    1. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

  1. SOLE VOTING POWER

0

  1. SHARED VOTING POWER

760,000

  1. SOLE DISPOSITIVE POWER

0

  1. SHARED DISPOSITIVE POWER

760,000

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

760,000

  1. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

[_]

  1. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

4.7%

  1. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IA, OO

CUSIP
No
49803V107
  1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Armistice Capital Master Fund Ltd.

    1. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  • (a) [_] (b) [_]

    1. SEC USE ONLY
    1. CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

  1. SOLE VOTING POWER

0

  1. SHARED VOTING POWER

760,000

  1. SOLE DISPOSITIVE POWER

0

  1. SHARED DISPOSITIVE POWER

760,000

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

760,000

  1. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

[_]

  1. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

4.7%

  1. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

CUSIP No
49803V107
1. NAME
OF
REPORTING
PERSONS
I.R.S.
IDENTIFICATION
NOS.
OF
ABOVE
PERSONS
(ENTITIES
ONLY)
Steven
Boyd
2. CHECK
THE
APPROPRIATE
BOX
IF
A
MEMBER
OF
A
GROUP
(SEE
INSTRUCTIONS)
3. SEC
USE
ONLY
4. CITIZENSHIP
OR
PLACE
OF
ORGANIZATION
United
States
of
America
NUMBER OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH
5. SOLE
VOTING
POWER
0
6. SHARED
VOTING
POWER
760,000
7. SOLE
DISPOSITIVE
POWER
0
8. SHARED
DISPOSITIVE
POWER
760,000
9. AGGREGATE
AMOUNT
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
760,000
10. CHECK
BOX
IF
THE
AGGREGATE
AMOUNT
IN
ROW
(9)
EXCLUDES
CERTAIN
SHARES
(SEE
INSTRUCTIONS)
11. PERCENT
OF
CLASS
REPRESENTED
BY
AMOUNT
IN
ROW
(9)

4.7%

  1. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IN, HC

[_]

(a) [_] (b) [_]

CUSIP No 49803V107
Item
1.
(a). Name
of
Issuer:
Kitov
Pharma
Ltd.
(b). Address
of
Issuer's
Principal
Executive
Offices:
One
Azrieli
Center,
Round
Tower
132
Menachem
Begin
Road,
Tel
Aviv,
6701101,
Israel
Item
2.
(a). Name
of
Person
Filing:
Armistice
Capital,
LLC
Armistice
Capital
Master
Fund
Ltd.
Steven
Boyd
(b). Address
of
Principal
Business
Office,
or
if
None,
Residence:
Armistice
Capital,
LLC
510
Madison
Avenue,
22nd
Floor
New
York,
New
York
10022
United
States
of
America
Armistice
Capital
Master
Fund
Ltd.
c/o
dms
Corporate
Services
Ltd.
20
Genesis
Close
P.O.
Box
314
Grand
Cayman
KY1-1104
Cayman
Islands
Steven
Boyd
c/o
Armistice
Capital,
LLC
510
Madison
Avenue,
22nd
Floor
New
York,
New
York
10022
United
States
of
America
(c) Citizenship:
Armistice
Capital,
LLC

Delaware
Armistice
Capital
Master
Fund
Ltd.

Cayman
Islands
Steven
Boyd

United
States
of
America
(d). Title
of
Class
of
Securities:
Ordinary
Shares,
no
par
value
(e). CUSIP
Number:

49803V107 [2] ____________________________

[2] Represents the CUSIP number for the American Depositary Shares, each representing 20 Ordinary Shares, no par value.

Item
3.
If
This
Statement
is
filed
pursuant
to
ss.240.13d-1(b)
or
240.13d-2(b),
or
(c),
check
whether
the
person
filing
is
a
(a) [_] Broker
or
dealer
registered
under
Section
15
of
the
Exchange
Act
(15
U.S.C.
78c).
(b) [_] Bank
as
defined
in
Section
3(a)(6)
of
the
Exchange
Act
(15
U.S.C.
78c).
(c) [_] Insurance
company
as
defined
in
Section
3(a)(19)
of
the
Exchange
Act
(15
U.S.C.
78c).
(d) [_] Investment
company
registered
under
Section
8
of
the
Investment
Company
Act
of
1940
(15
U.S.C.
80a-8).
(e) [_] An
investment
adviser
in
accordance
with
§
240.13d-1(b)(1)(ii)(E);
(f) [_] An
employee
benefit
plan
or
endowment
fund
in
accordance
with
§
240.13d-1(b)(1)(ii)(F);
(g) [_] A
parent
holding
company
or
control
person
in
accordance
with
Rule
13d-1(b)(1)(ii)(G);
(h) [_] A
savings
association
as
defined
in
Section
3(b)
of
the
Federal
Deposit
Insurance
Act
(12
U.S.C.1813);
(i) [_] A
church
plan
that
is
excluded
from
the
definition
of
an
investment
company
under
Section
3(c)
(14)
of
the
Investment
Company
Act
of
1940
(15
U.S.C.
80a-3);
(j) [_] Group,
in
accordance
with
s.240.13d-1(b)(1)(ii)(J).

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

Armistice Capital, LLC – 760,000 Armistice Capital Master Fund Ltd. – 760,000 Steven Boyd – 760,000

(b) Percent of class:

Armistice Capital, LLC – 4.7% Armistice Capital Master Fund Ltd. – 4.7% Steven Boyd – 4.7%

  • (c) Number of shares as to which the person has:
    • (i) Sole power to vote or to direct the vote

Armistice Capital, LLC – 0 Armistice Capital Master Fund Ltd. – 0 Steven Boyd – 0

(ii) Shared power to vote or to direct the vote

Armistice Capital, LLC – 760,000 Armistice Capital Master Fund Ltd. – 760,000 Steven Boyd – 760,000

(iii) Sole power to dispose or to direct the disposition of

Armistice Capital, LLC – 0 Armistice Capital Master Fund Ltd. – 0 Steven Boyd – 0

(iv) Shared power to dispose or to direct the disposition of

Armistice Capital, LLC – 760,000 Armistice Capital Master Fund Ltd. – 760,000 Steven Boyd – 760,000

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

N/A

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

June 11, 2018

(Date)

Armistice Capital, LLC*

By: /s/ Steven Boyd Steven Boyd Managing Member

Armistice Capital Master Fund Ltd.

By: /s/ Steven Boyd Steven Boyd Director

/s/ Steven Boyd* Steven Boyd

* This Reporting Person disclaims beneficial ownership in the Ordinary Shares, except to the extent of his or its pecuniary interest therein.

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

Exhibit A

AGREEMENT

The undersigned agree that this Schedule 13G dated June 11, 2018 relating to the Ordinary Shares, no par value, of Kitov Pharma Ltd. shall be filed on behalf of the undersigned.

Armistice Capital, LLC

By: /s/ Steven Boyd Steven Boyd Managing Member

Armistice Capital Master Fund Ltd.

By: /s/ Steven Boyd Steven Boyd Director

/s/ Steven Boyd Steven Boyd

Talk to a Data Expert

Have a question? We'll get back to you promptly.